The metabolism of fluorometholone by bovine cornea

Iqbal, Zafar; Watson, David; Midgley, John M.; Dennison, Philip R.; McGhee, Charles N J

doi:10.1016/0731-7085(93)80091-e

Cited by 8 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, it has been shown that fluorometholone has a relatively short half-life and rapid metabolism. 40 Dexamethasone was the most potent inhibitor in almost all conducted experiments. The different antilymphangiogenic potentials of these 3 corticosteroids should be taken into account when using them in clinical practice (eg, after keratoplasty).…”

Section: Commentmentioning

confidence: 99%

Suppression of Inflammatory Corneal Lymphangiogenesis by Application of Topical Corticosteroids

Hos

Saban²,

Bock³

et al. 2011

Arch Ophthalmol

View full text Add to dashboard Cite

Objectives:To analyze whether topical application of corticosteroids inhibits inflammatory corneal lymphangiogenesis and to study the potential underlying antilymphangiogenic mechanisms.Methods: Inflammatory corneal neovascularization was induced by suture placement, and the corneas were then treated with topical fluorometholone, prednisolone acetate, or dexamethasone sodium phosphate. After 1 week, the corneas were stained with lymphatic vessel endothelial hyaluronan receptor 1 for detection of pathological corneal lymphangiogenesis. The effect of these corticosteroids on macrophage recruitment was assessed via fluorescence-activated cell sorting analysis. The effect of these corticosteroids on proinflammatory cytokine expression by peritoneal exudate cells was tested via real-time polymerase chain reaction. Furthermore, the effect of steroid treatment on the proliferation of lymphatic endothelial cells was assessed via enzyme-linked immunosorbent assay.Results: Treatment with corticosteroids resulted in a significant reduction of inflammatory corneal lymphangiogenesis. The antilymphangiogenic effect of fluorometholone was significantly weaker than that of prednisolone and dexamethasone. Corneal macrophage recruitment was also significantly inhibited by the application of topical steroids. Treatment of peritoneal exudate cells with corticosteroids led to a significant downregulation of the RNA expression levels of tumor necrosis factor and interleukin 1␤. Additionally, proliferation of lymphatic endothelial cells was also inhibited.

show abstract

Section: Commentmentioning

confidence: 99%

Suppression of Inflammatory Corneal Lymphangiogenesis by Application of Topical Corticosteroids

Hos

Saban²,

Bock³

et al. 2011

Arch Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Fluorometholone alcohol 0.1% and loteprednol etabonate 0.5% are mild corticosteroids with low intraocular penetration 26 58. It has been established that fluorometholone alcohol, which has a low likelihood of elevating IOP and penetrates into human aqueous humour to a lesser extent than prednisolone or dexamethasone,8 undergoes local ocular metabolism and consequent inactivation in the cornea 62. According to corticosteroid penetration studies, fluorometholone alcohol 0.1%, loteprednol etabonate 0.5%, betamethasone phosphate 0.5% and prednisolone sodium phosphate 0.5% can be used for ocular surface diseases.…”

Section: Therapeutic Implications In the Management Of Anterior Segmementioning

confidence: 99%

Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance

Awan

Agarwal

Watson

et al. 2009

British Journal of Ophthalmology

View full text Add to dashboard Cite

Topical and subconjunctival corticosteroids are some of the most effective and compelling treatment options in ocular inflammatory diseases. A systematic review of literature indexed by Ovid MEDLINE & EMBASE was performed up to December 2008. There are few studies on their aqueous penetration in human subjects. This review article discusses the penetration of different ocular corticosteroids into human aqueous humour along with the therapeutic implications on management of ocular surface diseases, immune-related corneal diseases, anterior uveitis and postoperative anti-inflammatory use. In the context of the paucity of well-constructed, prospective clinical trials comparing the efficacy of different corticosteroids, it provides guiding principles for the use of topical corticosteroids. Dexamethasone alcohol 0.1% and prednisolone acetate 1% are potent corticosteroids, but the latter achieves the highest aqueous concentration within 2 h and maintains higher levels for 24 h. Subconjunctival corticosteroids provide very high concentrations in the aqueous which maintain higher concentrations for longer periods

show abstract

“…The CD46 gene located in the Regulators of Complement Activation (RCA) gene cluster, 1q32 [9], CD46, also known as membrane cofactor protein (MCP), is ubiquitously expressed on most cells (except erythrocytes), especially highly expressed on kidney cells [10], it acts as a C3b and C4b binding protein of human peripheral blood cells and kidney cells, which regulates complement activation by serving as a cofactor for the factor I-mediated cleavage of C3b and C4b that are deposited on host cells [11]. CD46 has four complement control protein (CCP) modules that house the sites for complement interaction.…”

Section: Introductionmentioning

confidence: 99%

Protein-losing enteropathy as a new phenotype in atypical hemolytic uremic syndrome caused by CD46 gene mutation and recovery from chronic kidney failure by eculizumab treatment

Wang,

Chen,

Han

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathies. Genetic defects in complement alternative pathway have been identified in 60-70% of aHUS individuals. Eculizumab is recommended as first-line therapy. Methods: We collected clinical data of a pediatric aHUS case, who accompanied with protein-losing enteropathy (PLE). Genetic testing was performed. Related literatures of aHUS combined with PLE were reviewed. Results: A 15-year-old Chinese girl was diagnosed with aHUS at 3.7-year- old, and suffered with five episodes, she showed completely resolved with plasma treatment. Severe gastrointestinal symptoms and hypoalbuminemia presented after first episode and protein-losing enteropathy (PLE) was diagnosed. A novel homozygous CD46 variant was identified and FACS showed significantly decreased CD46 expression. She presented a recent relapse with persistent GI symptoms and headache, and progressed to chronic kidney failure, peritoneal dialysis was initiated. Eculizumab was given after 8 months of last recurrence. Surprisingly, PLE was cured, Afterwards, dialysis could be discontinued, eGFR recovered to 44.8ml/min/1.73㎡. Review of literatures indicated PLE with thrombosis was caused by CD55 variants with a mechanism of hyperactivation of complement system. We firstly reported an aHUS case with PLE caused by CD46 variants, both symptoms of PLE and aHUS improved significantly in our case and cases reported with CD55 variants treated with eculizumab, which indicates PLE as a new symptom of aHUS in our case with CD46 variants. Conclusions: Our case expands phenotype of aHUS caused by CD46 mutation, and provide evidence of efficiency of eculizumab after a long chronic kidney failure phase.

show abstract

The metabolism of fluorometholone by bovine cornea

Cited by 8 publications

References 12 publications

Suppression of Inflammatory Corneal Lymphangiogenesis by Application of Topical Corticosteroids

Suppression of Inflammatory Corneal Lymphangiogenesis by Application of Topical Corticosteroids

Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance

Protein-losing enteropathy as a new phenotype in atypical hemolytic uremic syndrome caused by CD46 gene mutation and recovery from chronic kidney failure by eculizumab treatment

Contact Info

Product

Resources

About